U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H11ClN2O2.C6H14N2O2
Molecular Weight 408.879
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLONIXIN LYSINE

SMILES

NCCCC[C@H](N)C(O)=O.CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl

InChI

InChIKey=CVNFYQCHAWFYQI-ZSCHJXSPSA-N
InChI=1S/C13H11ClN2O2.C6H14N2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12;7-4-2-1-3-5(8)6(9)10/h2-7H,1H3,(H,15,16)(H,17,18);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1

HIDE SMILES / InChI

Description

Clonixin is a nonsteroidal agent. It is an anilino-nicotinic acid derivative. It is a drug of anti-inflammatory antipyretic and analgesic activity that produces minor digestive side-effects. At high concentrations, clonixin inhibited PGE2 formed by COX-2 and partly by COX-1 activity. The drug is indicated for the relief of headaches, muscle aches, joint, dental, ear, dysmenorrhea, post-traumatic, post-surgical, gynecological. Adverse effects are occasionally nausea, dizziness, and somnolence, were mild and transient. On rare occasions, and administering high doses, it is possible the appearance of dry mouth or constipation. Concomitant use of anticholinergic drugs to be avoided by the possibility that they enhance their effects atropine.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Dorixina
Palliative
Dorixina
Primary
Dorixina

PubMed

Sample Use Guides

In Vivo Use Guide
200 mg single dose
Route of Administration: Intravenous
In Vitro Use Guide
clonixin (Clx) between 1 x 10(-6) M and 3 x 10(-4) M, decreases the overshoot (OS), action potential amplitude (APA), Vmax and frequency of primary and subsidiary cells, however pacemaker cells differ in their sensitivity to Clx. At 2 x 10(-6) M, Clx completely blocked the spontaneous beating of primary cells.